Showing results (221-230 of 280) with videos related to
Sort By:
Pageof 28
Annals of Hematology|November 30, 2023
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agentsJan Philipp Bewersdorf, Rory M Shallis, Elad Sharon, et al.International Journal of Molecular Sciences|October 26, 2024
Immune Checkpoint Inhibitor Therapy and Associations with Clonal HematopoiesisAbhay Singh, Nuria Mencia Trinchant, Rahul Mishra, et al.Cancer|October 30, 2013
Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemiaHun Ju Lee, Josephia R Muindi, Wei Tan, et al.Blood|October 18, 2011
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemiaJudith E Karp, Tatiana I Vener, Mitch Raponi, et al.Blood Advances|October 9, 2020
Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentationsSimone Feurstein, Ayodeji Adegunsoye, Danijela Mojsilovic, et al.Blood|December 3, 2014
BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphomaCristina Correia, Paula A Schneider, Haiming Dai, et al.Blood|December 26, 2008
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposideJudith E Karp, Karen Flatten, Eric J Feldman, et al.Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2013
Myelodysplastic syndromes: clinical practice guidelines in oncologyPeter L Greenberg, Eyal Attar, John M Bennett, et al.Cancer|December 7, 2017
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemiaGail J Roboz, Hagop M Kantarjian, Karen W L Yee, et al.Blood Advances|January 26, 2022
Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapyJurjen Versluis, Manu Pandey, Yael Flamand, et al.Pageof 28